News & Comment

Filter By:

Article Type
Year
  • Lessons from the rapid development, manufacture and distribution of vaccines against COVID-19 must be broadly applied to expedite vaccine development for other infectious diseases.

    Editorial
  • Scientific and medical research conducted in space can bring benefits for all humankind, but this will require commercial space flight companies to embrace open data principles.

    Editorial
  • Are healthcare systems prepared to deal with cost and accessibility of gene therapies on a global scale?

    Editorial
  • Telehealth has emerged as an unexpected silver lining of the COVID-19 pandemic, improving access to care and facilitating a transition toward digital medicine. Cementing these gains now could help make healthcare more equitable once the pandemic has ended.

    Editorial
  • The surge in COVID-19 cases in India and Brazil highlights the need to improve vaccine manufacturing capacity and investment in public health at the local level.

    Editorial
  • Enhancing population diversity in genetic databases and evaluating genetic scores in conjunction with other disease factors will be needed to ensure a more equitable impact of precision medicine.

    Editorial
  • Gene-therapy trials are on the rise, but more needs to be done to understand the long-term risks associated with this type of treatment.

    Editorial
  • The COVID-19 pandemic has opened a window of opportunity for rethinking the way countries prepare for public-health crises. This window must not be wasted.

    Editorial
  • Diverging from tested vaccination regimens without scientific evidence could undermine public confidence in vaccines against COVID-19 and the success of a global vaccination strategy to curtail the pandemic.

    Editorial
  • The United Nations Assembly has named 2021 the International Year of Peace and Trust. In that spirit, the world can look forward with hope to the international collaborations spearheaded by the World Health Organization and consider the challenges the agency has yet to face.

    Editorial